Insiders · ESPR

ESPR insider transactions

Esperion Therapeutics Inc. (ESPR) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for ESPR

• 4d
  Director Hoffman Robert E. returned 85,153 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover withholding tax

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 4d
  Director Carroll J Martin returned 177,523 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover withholding tax

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 4d
  Director Shepard Jay returned 164,472 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy tax liability

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 4d
  Director Fischer Seth H. Z. returned 141,023 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 4d
  Director Thompson John Craig returned 79,873 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 4d
  Chief Commercial Officer Harlow John B. Jr. returned 424,536 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 4d
  Chief Legal Officer Looker Benjamin returned 667,524 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 4d
  Chief Financial Officer Halladay Benjamin returned 705,410 shares to the company, closing all direct ownership in the company (SEC Form 4) (for tax liability)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 4d
  President and CEO Koenig Sheldon L. returned 2,121,094 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 29d
  Chief Legal Officer Looker Benjamin sold $37,305 worth of shares (11,824 units at $3.16), decreasing direct ownership by 2% to 667,524 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 29d
  President and CEO Koenig Sheldon L. sold $169,070 worth of shares (53,588 units at $3.15), decreasing direct ownership by 2% to 2,119,111 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 29d
  Chief Financial Officer Halladay Benjamin sold $33,989 worth of shares (10,773 units at $3.15), decreasing direct ownership by 2% to 702,829 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 46d
  Director Thompson John Craig was granted 79,873 shares (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 46d
  Director Shepard Jay was granted 79,873 shares, increasing direct ownership by 94% to 164,472 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 46d
  Director Hoffman Robert E. was granted 79,873 shares, increasing direct ownership by 1,513% to 85,153 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 46d
  Director Fischer Seth H. Z. was granted 79,873 shares, increasing direct ownership by 131% to 141,023 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 46d
  Director Carroll J Martin was granted 79,873 shares, increasing direct ownership by 82% to 177,523 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 121d
  SEC Form 4 filed by Koenig Sheldon L.

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 121d
  SEC Form 4 filed by Looker Benjamin

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 121d
  SEC Form 4 filed by Halladay Benjamin

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 123d
  Chief Legal Officer Looker Benjamin was granted 300,840 shares, increasing direct ownership by 78% to 685,056 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 123d
  President and CEO Koenig Sheldon L. was granted 723,760 shares, increasing direct ownership by 49% to 2,198,277 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 123d
  Chief Financial Officer Halladay Benjamin was granted 247,430 shares, increasing direct ownership by 52% to 720,026 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 177d
  General Counsel Looker Benjamin sold $4,868 worth of shares (1,689 units at $2.88), decreasing direct ownership by 0.44% to 384,216 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 211d
  President and CEO Koenig Sheldon L. sold $177,200 worth of shares (48,244 units at $3.67), decreasing direct ownership by 3% to 1,470,587 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 211d
  Chief Financial Officer Halladay Benjamin sold $26,905 worth of shares (7,337 units at $3.67), decreasing direct ownership by 2% to 467,525 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 211d
  General Counsel Looker Benjamin sold $23,898 worth of shares (6,517 units at $3.67), decreasing direct ownership by 2% to 385,905 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 221d
  Chief Commercial Officer Harlow John B. Jr. was granted 424,536 shares (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 242d
  SEC Form 3 filed by new insider Harlow John B. Jr.

  3 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 302d
  General Counsel Looker Benjamin sold $17,573 worth of shares (6,267 units at $2.80), decreasing direct ownership by 2% to 393,670 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 302d
  President and CEO Koenig Sheldon L. sold $79,254 worth of shares (28,427 units at $2.79), decreasing direct ownership by 2% to 1,518,831 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 302d
  Chief Financial Officer Halladay Benjamin sold $19,785 worth of shares (7,046 units at $2.81), decreasing direct ownership by 1% to 474,862 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 364d
  General Counsel Looker Benjamin sold $1,470 worth of shares (1,304 units at $1.13), decreasing direct ownership by 0.32% to 399,937 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 364d
  Chief Financial Officer Halladay Benjamin sold $12 worth of shares (11 units at $1.11), decreasing direct ownership by 0.00% to 474,462 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 380d
  SEC Form 4 filed by Director Thompson John Craig

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 380d
  SEC Form 3 filed by new insider Thompson John Craig

  3 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 394d
  General Counsel Looker Benjamin sold $7,398 worth of shares (6,422 units at $1.15), decreasing direct ownership by 2% to 401,241 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 394d
  President and CEO Koenig Sheldon L. sold $33,796 worth of shares (30,474 units at $1.11), decreasing direct ownership by 2% to 1,541,488 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 394d
  Chief Financial Officer Halladay Benjamin sold $8,328 worth of shares (7,229 units at $1.15), decreasing direct ownership by 2% to 474,473 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 410d
  Director Carroll J Martin was granted 33,000 shares, increasing direct ownership by 51% to 97,650 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 410d
  Director Fischer Seth H. Z. was granted 33,000 shares, increasing direct ownership by 117% to 61,150 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 410d
  Director Hoffman Robert E. was granted 5,280 shares (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 410d
  Director Rocamboli Stephen was granted 33,000 shares, increasing direct ownership by 91% to 69,261 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 410d
  Director Shepard Jay was granted 33,000 shares, increasing direct ownership by 64% to 84,599 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 410d
  SEC Form 4 filed by Director Vitullo Nicole

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 410d
  SEC Form 4 filed by Director Woody Tracy M

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 452d
  Chief Commercial Officer Warren Eric sold $106 worth of shares (108 units at $0.98), decreasing direct ownership by 0.03% to 370,218 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 452d
  Chief Financial Officer Halladay Benjamin sold $8 worth of shares (8 units at $0.96), decreasing direct ownership by 0.00% to 481,702 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 471d
  SEC Form 4 filed by Director Hoffman Robert E.

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 471d
  SEC Form 3 filed by new insider Hoffman Robert E.

  3 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 485d
  Chief Financial Officer Halladay Benjamin sold $5,242 worth of shares (3,535 units at $1.48), decreasing direct ownership by 0.73% to 481,710 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 485d
  Chief Commercial Officer Warren Eric sold $3,618 worth of shares (2,433 units at $1.49), decreasing direct ownership by 0.65% to 370,326 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 485d
  President and CEO Koenig Sheldon L. sold $19,623 worth of shares (13,047 units at $1.50), decreasing direct ownership by 0.82% to 1,571,962 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 487d
  President and CEO Koenig Sheldon L. was granted 840,000 shares, increasing direct ownership by 113% to 1,585,009 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 487d
  Chief Financial Officer Halladay Benjamin was granted 238,000 shares, increasing direct ownership by 96% to 485,245 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 487d
  Chief Commercial Officer Warren Eric was granted 213,000 shares, increasing direct ownership by 133% to 372,759 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 487d
  General Counsel Looker Benjamin was granted 224,000 shares, increasing direct ownership by 122% to 407,663 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 512d
  Chief Commercial Officer Warren Eric sold $446 worth of shares (239 units at $1.87), decreasing direct ownership by 0.15% to 159,759 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 512d
  Chief Financial Officer Halladay Benjamin sold $20 worth of shares (11 units at $1.86), decreasing direct ownership by 0.00% to 240,671 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 542d
  Chief Financial Officer Halladay Benjamin sold $20 worth of shares (9 units at $2.27), decreasing direct ownership by 0.00% to 240,682 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)